RE:RE:RE:RE:RE:SZLS website has been updatedWe will soon get to see Aristotle revenue growth in the next earnings release.
That should be able to give us a base.
From there we want to see revenue growth in Aristotle, new announcements, and marketing,
Knowing that Care Oncology is profitable and bringing in strong revenue will also be very reasuring, and should earase the fears that their LOI with them isnt a waste of money.
With Aristotle now being available to the public in America Via their website, they now have access to 328 million people, who are able to connect to a doctor through their phones and computers to have a webchat to have the doctor prescribe the test, Thus beginning their revenue stream. Either they just get the test, dont have cancer and move on, paying us $1500, or they add minimum 2 years of treatment, including more tests, consultations, pills, etc...
The interview posted yesterday is very reasuring that Care Oncology is a smooth sailing company and has both feet through the door, and are very eager to use Aristotle to its fullest potential.
With their Covid revenue continuing to be on pace with their prospectus 1 year and a half in, it is still flowing steady and funding Aristotles intigration into the market.
Very good times ahead for Stage Zero Life Sciences.
Now lets start marketing.
Cheers,
Bully